A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms IO-PAZ
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 08 Dec 2018 Planned End Date changed from 27 May 2021 to 27 Aug 2021.
- 28 Sep 2018 Planned End Date changed from 26 Feb 2021 to 27 May 2021.
- 18 May 2018 Planned End Date changed from 28 Jan 2021 to 26 Feb 2021.